Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
Novartis has teamed up with AI-led biotech Relation Therapeutics in a deal worth up to approximately $1.7bn to discover and …
Post
-
-
Moderna signs deal worth up to $503m with Nanexa
Moderna has entered a licence agreement with Nanexa to add tailored release profiles to its injectable drugs. According to the contract, …
-
UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments
The UK Government has cut its innovative medicine rebate rate by more than a third in a move likely to …
-
Pfizer plans job cuts in Switzerland to reduce expenses
Pfizer is set to cut jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by …
-
Boehringer’s Jascayd gains China’s NMPA approval for PPF
China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis (PPF). The …
-
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor
Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) …
-
Crenolanib delivers incremental benefit in FLT3/NPM1 co-mutated AML
Arog Pharmaceuticals presented new results from a Phase III trial at the American Society of Hematology (ASH) Annual Meeting 2025, …
-
Cell and gene therapy investment strategy pivots as funding dries up
Companies looking to push into the gene therapy (CGT) sector are navigating a more selective funding landscape amid a wider …
-
Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility
American pharmaceutical giant Eli Lilly has tapped Huntsville, Alabama, as the location for its third orforglipron manufacturing facility. Set to enter …
-
Formycon and Zydus sign exclusive agreement for FYB206 supply
Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab), …
-
ASH 2025: golcadomide + rituximab combo shows standout potential in R/R FL
Bristol Myers Squibb’s golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as monotherapy and in …
-
Bio-based plastics for biopharma: How is parenteral packaging adopting eco-design?
In a parenteral packaging world often dominated by discussion of vials, stoppers, and pre-filled syringes, flip caps rarely take centre …
-
Health Canada approves Biogen’s Zurzuvae for PPD treatment
Biogen has received a notice of compliance (NOC) from Health Canada for Zurzuvae (zuranolone), a neuroactive steroid (NAS), as a treatment …
-
BIOSECURE Act set for Congress vote after inclusion in annual defence bill
After years in legislative limbo, the BIOSECURE Act – albeit with a softer framework – is poised to enter the …
-
Mirum to buy Bluejay for up to $820m in rare liver disease push
Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics in a deal worth up to $820m, adding a Phase III liver …
